MPN

Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with Venclexta showing no clear benefit.

Long-term follow-up data from the phase 3 MANIFEST 2 clinical trial have been revealed.

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, myelofibrosis, and CLL.

Cytopenia at myelofibrosis diagnosis raises risk of acute myeloid leukemia and lowers survival, highlighting the need for tailored treatment strategies.

Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.

Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.

Katherine has an exquisite instinct for understanding that there is a context to each patient’s diagnosis that is just as important to understand.

A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.

JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.

Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.

CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital.

A push for answers led to a rare blood disorder diagnosis after Joy’s symptoms were initially dismissed.

Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.

An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert.

Machine learning model improves transplant risk assessment for patients with myelofibrosis, helping clinicians make informed decisions, as per an expert.

Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.

Dr. Richard “Rick" Winneker discussed advice that he would provide to patients faced with a myeloproliferative neoplasm diagnosis.

One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment that remains strong despite some setbacks.

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia.

A patient with MPN urges others to ask questions about treatment options, which may also include inquiring about clinical trials.

A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.

An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on research and treatment development.

A health care professional talks about the importance of a supportive care team, especially since every patient with MPNs presents differently.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.